China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
Address: Guilinyang Industrial Development Zone, Haikou, Hainan, China
Tel: 0898-65710069
Hainan Dongfang Dahui Starch Products Co., Ltd. is a national key leading enterprise in agricultural industry which owned the state’s financial investment, integrating cassava cultivation, production , deep-processing, etc, and owning 6 production lines to produce chemical modified starch, drying modified starch, pre-gelatinized modified starch, glutinous rice starch, etc, which supply series of high-quality cassava starch and modified starch products, widely used in the fields of food, paper, textile, feed, construction materials, petroleum, chemical industry, etc.. It has passed Certification of ISO9001-2008 Quality Management System, and HACCP-EC-01 Certification of Food Safety Management System. In 2006, it is honored as National Agricultural Products Processing Demonstration Enterprise by China Agricultural Department. Meanwhile, it is the only manufacture of organic cassava starch in China, which passed the organic certification of Canada, USDA, IFOAM and OFDC organization.
Food Series
Modified starch glue prime
Feed Series
Chemical Building Materials Series
Modified starch glue prime
Petroleum chemicals Series
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…
The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic,…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.…
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
See our Cookie Privacy Policy Here
